Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4.

Authors: Samuels, Eric R; Sevrioukova, Irina F

Published In Bioorg Med Chem, (2020 03 15)

Abstract: Identification of structural determinants required for potent inhibition of drug-metabolizing cytochrome P450 3A4 (CYP3A4) could help develop safer drugs and more effective pharmacoenhancers. We utilize a rational inhibitor design to decipher structure-activity relationships in analogues of ritonavir, a highly potent CYP3A4 inhibitor marketed as pharmacoenhancer. Analysis of compounds with the R1 side-group as phenyl or naphthalene and R2 as indole or naphthalene in different stereo configuration showed that (i) analogues with the R2-naphthalene tend to bind tighter and inhibit CYP3A4 more potently than the R2-phenyl/indole containing counterparts; (ii) stereochemistry becomes a more important contributing factor, as the bulky side-groups limit the ability to optimize protein-ligand interactions; (iii) the relationship between the R1/R2 configuration and preferential binding to CYP3A4 is complex and depends on the side-group functionality/interplay and backbone spacing; and (iv) three inhibitors, 5a-b and 7d, were superior to ritonavir (IC50 of 0.055-0.085 μM vs. 0.130 μM, respectively).

PubMed ID: 32044230 Exiting the NIEHS site

MeSH Terms: Cytochrome P-450 CYP3A Inhibitors/chemical synthesis; Cytochrome P-450 CYP3A Inhibitors/chemistry; Cytochrome P-450 CYP3A Inhibitors/pharmacology*; Cytochrome P-450 CYP3A/metabolism*; Dose-Response Relationship, Drug; Humans; Hydrophobic and Hydrophilic Interactions; Molecular Structure; Ritonavir/chemical synthesis; Ritonavir/chemistry; Ritonavir/pharmacology*; Structure-Activity Relationship

to Top